TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 2.63nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 6nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-33P] ATP. 33...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 9nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence ATP/ [gamma-32P] ATP. 32P incorpo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 9nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 9.5nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 9.5nMpH: 7.5 T: 2°CAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 10nMpH: 7.4 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 22nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 24nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 24nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 25nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 35nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 44nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 47nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 53nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 60nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 60nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 60nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 60nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence ATP/ [gamma-32P] ATP. 32P incorpo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 67nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 70nMpH: 7.5 T: 2°CAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 75nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 77nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 80nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 80nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 80nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 94nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 100nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence ATP/ [gamma-32P] ATP. 32P incorpo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 103nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 110nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence ATP/ [gamma-32P] ATP. 32P incorpo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 140nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 140nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 150nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 150nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 180nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 180nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 180nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMAssay Description:The enzyme was assayed with substrate histone H1 in the presence of 12.5 uM ATP/[gamma-32P] ATP. IC50 is the inhibitor concentration, which inhibits ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Marthasterias glacialis (starfish))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 200nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair